Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers

Louisa Mezache, Bernard Paniccia, Angelique Nyinawabera, Gerard J Nuovo, Louisa Mezache, Bernard Paniccia, Angelique Nyinawabera, Gerard J Nuovo

Abstract

Programmed death ligand 1 (PD L1) expression can reduce the immune response in both infectious diseases and cancers. We thus examined PD L1 expression in cervical intraepithelial neoplasias (CINs) and cancers since they each reflect infection by human papillomavirus (HPV). PD L1 protein was not evident by immunohistochemistry in histologically normal cervical epithelia (0/55) even when adjacent to CIN or cancer. PD L1 expression was much increased in CINs (20/21=95%) and cervical squamous cell cancer (56/70=80%) and localized to the dysplastic/neoplastic squamous cells and mononuclear cells, respectively. There was also a significant increase (each P<0.001) in PD L1 detection in mononuclear cells when comparing cervical squamous cell cancers to endometrial (22/115=19%) and ovarian adenocarcinomas (5/40=13%). Co-expression analyses showed that the primary inflammatory cell that contained PD L1 was the CD8+ lymphocyte that strongly concentrated around the dysplastic CIN cells and nests of invasive squamous cancer cells. These data show that PD L1 is a solid biomarker of productive HPV infection of the cervix and that it is significantly upregulated in both the carcinoma and surrounding inflammatory cells in cervical cancer when compared with other gynecologic malignancies. This suggests that anti-PD L1 therapy may have a role in the treatment of cervical cancer.

References

    1. Nature. 2014 Nov 27;515(7528):563-7
    1. J Virol. 1988 Jan;62(1):84-90
    1. Cancer Treat Rev. 2004 Apr;30(2):205-11
    1. Cancer J. 2003 Sep-Oct;9(5):360-7
    1. Vaccine. 2006 Jul 7;24(27-28):5571-83
    1. Nature. 2014 Nov 27;515(7528):568-71
    1. Mod Pathol. 2012 Oct;25(10):1333-44
    1. Mod Pathol. 2010 Aug;23(8):1045-51
    1. J Immunol. 2010 Dec 1;185(11):7107-14
    1. JAMA. 2014 Feb 12;311(6):597-603
    1. Immunol Invest. 2009;38(7):624-38
    1. JAMA. 1990 Mar 2;263(9):1223-6
    1. Obstet Gynecol. 1990 Feb;75(2):223-6
    1. Lancet. 2001 Nov 24;358(9295):1782-3
    1. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
    1. Immunology. 2013 Aug;139(4):513-22
    1. Clin Cancer Res. 2009 Oct 15;15(20):6341-7
    1. J Natl Cancer Inst. 2000 May 3;92(9):690-8
    1. Gynecol Oncol. 2006 Jul;102(1):22-31
    1. J Clin Pathol. 2002 Apr;55(4):244-65
    1. Am J Pathol. 1991 Nov;139(5):1037-45

Source: PubMed

3
Abonneren